Lactobacillus is Generally Resistant to Cephalexin
Lactobacillus species demonstrate intrinsic resistance to cephalosporins, including cephalexin, and should not be expected to be susceptible to this antibiotic. This resistance pattern is well-documented in both clinical isolates and probiotic strains.
Evidence from FDA Drug Labeling and Clinical Studies
The FDA-approved drug label for cephalexin explicitly lists its spectrum of activity, which includes gram-positive organisms like Staphylococcus aureus and Streptococcus species, and gram-negative organisms like E. coli, Haemophilus influenzae, and Proteus mirabilis 1. Notably absent from this list is any mention of Lactobacillus species, indicating these organisms are not within cephalexin's expected antimicrobial coverage.
Clinical research directly confirms this resistance pattern. A study of 85 Lactobacillus bacteremia cases found that while most isolates demonstrated low MICs to imipenem, piperacillin-tazobactam, erythromycin, and clindamycin, they showed variable susceptibility to penicillin and cephalosporins, with cephalosporins generally showing poor activity 2. The MICs of cephalosporins varied considerably, with cefuroxime demonstrating higher activity than ceftriaxone, but overall cephalosporin activity remained limited.
Resistance Patterns in Probiotic and Food-Associated Strains
Research on Lactobacillus strains from fermented foods confirms this intrinsic resistance. A study examining lactic acid bacteria from ethnic fermented foods found that Lactobacillus species were sensitive to most common antibiotics except for cloxacillin, cephalexin, and cephalothin 3. This demonstrates that resistance to first-generation cephalosporins like cephalexin is a consistent characteristic across different Lactobacillus strains.
Most strikingly, researchers successfully developed a highly cephalexin-resistant Lactiplantibacillus plantarum strain by exposing it to gradually increasing concentrations of cephalexin, ultimately achieving an MIC increase from 16 to 4096 μg/mL 4. This study exploited the natural resistance mechanisms of Lactobacillus to create a strain that could survive alongside cephalexin treatment, specifically because the baseline resistance of Lactobacillus to cephalexin made this development feasible.
Clinical Implications
- Do not prescribe cephalexin with the expectation of treating Lactobacillus infections (though these are rare and typically occur only in immunocompromised patients)
- If treating a documented Lactobacillus bacteremia or infection, consider agents with demonstrated activity: imipenem, piperacillin-tazobactam, erythromycin, or clindamycin 2
- The intrinsic resistance of Lactobacillus to cephalosporins is actually beneficial when using probiotic Lactobacillus strains during antibiotic therapy, as it allows the probiotic to survive and potentially mitigate antibiotic-associated dysbiosis 4
In summary, cephalexin lacks clinically meaningful activity against Lactobacillus species due to intrinsic resistance mechanisms, and alternative antibiotics should be selected if treatment of Lactobacillus is required.